Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 2:39 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 79 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Anti-Arrhythmics Clear all
Completed No phase listed Observational

Comparison of QT Interval Readings Between Smartwatch Combined With Cardiologs Artificial Intelligence and 12-lead ECG

NCT05161065
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Cardiologs
Device
Lead sponsor
Cardiologs Technologies
Industry
Eligibility
22 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Nov 3, 2026, 2:39 PM EST
Completed Phase 3 Interventional Results available

First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Atrial Fibrillation Treatment (The RAAFT Study)

NCT00392054
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Pulmonary Vein Isolation performed by Catheter Ablation, Conventional Antiarrhythmic Drug Therapy
Procedure · Drug
Lead sponsor
Population Health Research Institute
Other
Eligibility
19 Years to 75 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
2
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2020 · Synced Nov 3, 2026, 2:39 PM EST
Completed Phase 3 Interventional Results available

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

NCT01639495
View directory record Official record
Conditions
Drug Refractory Symptomatic Paroxysmal Atrial Fibrillation
Interventions
THERMOCOOL® SMARTTOUCH™ Catheter
Device
Lead sponsor
Biosense Webster, Inc.
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
20
States / cities
Birmingham, Alabama • Stanford, California • Orlando, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Nov 3, 2026, 2:39 PM EST
Completed Phase 3 Interventional

Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Male Subjects

NCT00126061
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
Tedisamil sesquifumarate
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
4
States / cities
Los Angeles, California • Santa Ana, California • Honolulu, Hawaii + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2015 · Synced Nov 3, 2026, 2:39 PM EST
Terminated Not applicable Interventional

Necessity of Anti-Arrhythmic Medication After Surgical Ablation for Atrial Fibrillation

NCT01416935
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
No Amiodarone
Other
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Nov 3, 2026, 2:39 PM EST
Terminated Phase 3 Interventional Results available

Study of HD Mesh Ablation System for Treatment of Paroxysmal Atrial Fibrillation

NCT00741611
View directory record Official record
Conditions
Paroxysmal Atrial Fibrillation
Interventions
HD Mesh Ablation System, Anti-arrhythmic drugs
Device · Drug
Lead sponsor
C. R. Bard
Industry
Eligibility
21 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
13
States / cities
San Diego, California • Aurora, Colorado • Gainesville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2012 · Synced Nov 3, 2026, 2:39 PM EST
Not listed Phase 4 Interventional

Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure

NCT04160000
View directory record Official record
Conditions
Atrial Fibrillation, Heart Failure, Diastolic Heart Failure
Interventions
Catheter ablation, Rate or Rhythm control antiarrhythmic drugs for atrial fibrillation, Insertion of CardioMems Hemodynamic monitor, Empiric heart failure drug therapy
Device · Drug
Lead sponsor
Electrophysiology Research Foundation
Other
Eligibility
18 Years to 75 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
7
States / cities
Flagstaff, Arizona • Jonesboro, Arkansas • Littleton, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Nov 3, 2026, 2:39 PM EST
Withdrawn Not applicable Interventional Accepts healthy volunteers

Acute Mechanical Response to Anti-arrhythmic Drug Therapy

NCT02575534
View directory record Official record
Conditions
Arrhythmias
Interventions
Procainamide
Drug
Lead sponsor
Evan Adelstein, MD
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Nov 3, 2026, 2:39 PM EST
Completed Phase 3 Interventional

First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Persistent Atrial Fibrillation Treatment (RAAFT-3)

NCT04037397
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Anti Arrhythmics, Pulmonary Vein Isolation performed by Radio Frequency Catheter Ablation
Drug · Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
5
States / cities
Tucson, Arizona • The Bronx, New York • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Nov 3, 2026, 2:39 PM EST
Withdrawn Phase 4 Interventional

Catheter Ablation for Recently Diagnosed Paroxysmal Atrial Fibrillation

NCT01505296
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Antiarrhythmic drug, Catheter ablation
Drug · Procedure
Lead sponsor
Valley Health System
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Ridgewood, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 16, 2014 · Synced Nov 3, 2026, 2:39 PM EST
Completed No phase listed Observational Results available

QT Changes as Detected From LINQ ECG During Antiarrhythmic Loading (LINQ QT)

NCT05488470
View directory record Official record
Conditions
Atrial Arrhythmia, QT Interval, Variation in, Arrhythmias, Cardiac
Interventions
LINQ/LINQ II
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Jacksonville, Florida • Columbus, Ohio • Coos Bay, Oregon
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Nov 3, 2026, 2:39 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

CAEB071 Thorough QTc Study in Healthy Volunteers

NCT01594255
View directory record Official record
Conditions
Healthy
Interventions
sotrastaurin, placebo to sotrastaurin, Avelox
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2012 · Synced Nov 3, 2026, 2:39 PM EST
Completed Phase 2 Interventional

Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of SSR149744c 100 or 300 mg for the Prevention of ventrICular ARrhythmia-triggered Icd interventiOnS

NCT00232297
View directory record Official record
Conditions
Arrhythmia, Tachycardia, Ventricular, Ventricular Fibrillation
Interventions
SSR149744C
Drug
Lead sponsor
Sanofi
Industry
Eligibility
21 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 8, 2012 · Synced Nov 3, 2026, 2:39 PM EST
Withdrawn Phase 4 Interventional

Comparison of Reverse Remodeling and PVI Versus CFAE and/or Linear Lesions and PVI for Persistent AF

NCT01877473
View directory record Official record
Conditions
Persistent Atrial Fibrillation
Interventions
Ablation
Procedure
Lead sponsor
Valley Health System
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Ridgewood, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 17, 2014 · Synced Nov 3, 2026, 2:39 PM EST
Completed Not applicable Interventional Results available

Amiodarone for the Prevention of Reperfusion Ventricular Fibrillation

NCT00587483
View directory record Official record
Conditions
Other Intraoperative Cardiac Functional Disturbances During Cardiac Surgery
Interventions
Lidocaine, Amiodarone, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 11, 2011 · Synced Nov 3, 2026, 2:39 PM EST
Completed Not applicable Interventional Results available

A Study of the Effectiveness of Anti-Arrhythmic Medications After Atrial Fibrillation Ablation

NCT00408200
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
propafenone; flecainide; sotalol; dofetilide, Radiofrequency catheter ablation
Drug · Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced Nov 3, 2026, 2:39 PM EST
Completed Phase 3 Interventional Results available

Tailored Treatment of Permanent Atrial Fibrillation

NCT00514735
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Medtronic Cardiac Ablation System, Class I or III Antiarrhythmic Medications
Procedure · Drug
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years to 70 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
23
States / cities
Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Nov 3, 2026, 2:39 PM EST
Completed Phase 3 Interventional Results available

Multicenter Study of Antiarrhythmic Medications for Treatment of Infants With Supraventricular Tachycardia

NCT00390546
View directory record Official record
Conditions
Supraventricular Tachycardia
Interventions
Digoxin, Propranolol
Drug
Lead sponsor
University of British Columbia
Other
Eligibility
Up to 4 Months
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
10
States / cities
Los Angeles, California • Orange, California • Kansas City, Missouri + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Nov 3, 2026, 2:39 PM EST
Terminated Not applicable Interventional Results available

Pilot Study of Catheter Ablation for Ventricular Tachycardia in Patients With an Implantable Cardioverter Defibrillator

NCT01576042
View directory record Official record
Conditions
Ventricular Tachycardia
Interventions
amiodarone, sotalol, Biosense Webster's NAVI-STAR Thermo-Cool
Drug · Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
5
States / cities
Baltimore, Maryland • Durham, North Carolina • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Nov 3, 2026, 2:39 PM EST
Terminated Not applicable Interventional

Strategies in Patients Undergoing Repeat AF Ablation

NCT05185310
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Ablation
Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 9, 2024 · Synced Nov 3, 2026, 2:39 PM EST
Completed Phase 2 Interventional

Efficacy and Safety Study of an Antiarrhythmic Drug to Treat Atrial Fibrillation in Patients With Pacemakers

NCT00389792
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
ATI-2042, ATI-2042 200 mg
Drug
Lead sponsor
ARYx Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
27
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2009 · Synced Nov 3, 2026, 2:39 PM EST
Completed Not applicable Interventional

Comparison of Recurrence of Atrial Fibrillation Post Cryoballon Ablation During the 90-day Blanking Period-with and Without Anti-arrhythmic Drug Therapy

NCT02913014
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
No AAD post Ablation.
Other
Lead sponsor
Prisma Health-Midlands
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Nov 3, 2026, 2:39 PM EST
Terminated Phase 2 Interventional

Study Evaluating GAP-486 on Heart Rhythm in Patients With Coronary Artery Disease

NCT00137332
View directory record Official record
Conditions
Arrhythmia
Interventions
GAP-486 (ZP-123), 0.9% Sodium Chloride, USP
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
19
States / cities
Sacramento, California • San Francisco, California • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2007 · Synced Nov 3, 2026, 2:39 PM EST
Terminated Phase 4 Interventional Results available

Effect of Dronedarone on Atrial Fibrosis Progression and Atrial Fibrillation Recurrence

NCT04704050
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Fibrillation Recurrent
Interventions
dronedarone 400 mg Oral Tablet, Placebo
Drug
Lead sponsor
Tulane University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Colorado Springs, Colorado • Atlanta, Georgia • New Orleans, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Nov 3, 2026, 2:39 PM EST